Choong Ang Vaccine Laboratory
KKRX:0720208,850.00
KRW
-100.00
(-1.12%)
ISIN
KR7072020001
Return %
Stock
S&P 500
1Y
-7.04
14.20
3Y
-15.71
81.12
5Y
-44.86
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- In-Joong Yoon
- Full Time Employees
- 194
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Daejeon South Korea
- IPO Date
- Oct 31, 2003
- Website
- cavac.co.kr
- Similar Companies
- Business
- Choong Ang Vaccine Laboratories Co., Ltd. (CAVAC) is a South Korea-based biotechnology and animal health company primarily engaged in the research, development, manufacturing, and distribution of veterinary biological products, vaccines, pharmaceuticals, and diagnostic reagents. Founded in 1968 and headquartered in Daejeon, South Korea, the company operates under KOSDAQ ticker 072020. Choong Ang Vaccine Laboratories serves livestock producers, veterinary clinics, agricultural cooperatives, and public epidemic prevention authorities across domestic and international markets. The company's core product portfolio encompasses swine biologicals under the SuiShot brand, including vaccines for porcine epidemic diarrhea (PED-X), porcine reproductive and respiratory syndrome (PRRS), porcine circovirus type 2 (SuiShot Circo-One), swine erysipelas, and mycoplasmal pneumonia; poultry vaccines marketed under the Fowlshot brand, targeting avian influenza, Newcastle disease, infectious bronchitis, and fowl adenovirus; companion animal healthcare products under the CaniShot and FelliShot brands, comprising multivalent canine vaccines for distemper, infectious hepatitis, parvovirus, parainfluenza, and leptospirosis, as well as kennel cough, rabies, and feline viral combinations; bovine health solutions, providing preventative vaccines against bovine viral diarrhea and respiratory disease complexes; specialized biological formulations, including wildlife oral rabies bait vaccines, viral hemorrhagic disease vaccines for rabbits, and aquatic bacterial vaccines for olive flounder; and animal diagnostic solutions, including purified protein derivative (PPD) tuberculin reagents and diagnostic antigens. Choong Ang Vaccine Laboratories operates research and development facilities in Daejeon alongside Good Manufacturing Practice (GMP)-certified production plants in Nonsan, Chungcheongnam-do, exporting its products to more than 20 countries across East Asia, Southeast Asia, the Middle East, and Latin America. In recent developments, Choong Ang Vaccine Laboratories has accelerated its international commercial expansion through strategic distribution agreements, including partnerships with Elanco Animal Health to introduce products such as SuiShot Circo-One into international markets including China and Brazil. Furthermore, the company has attained regulatory approvals for new biological innovations, including its CaniShot oral rabies bait vaccine, while continuously expanding production capacity at its Nonsan manufacturing site and advancing R&D for next-generation swine and poultry preventative formulations to address evolving global animal health epidemics.